These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 23851282)

  • 21. Engineered antibody Fc variants with enhanced effector function.
    Lazar GA; Dang W; Karki S; Vafa O; Peng JS; Hyun L; Chan C; Chung HS; Eivazi A; Yoder SC; Vielmetter J; Carmichael DF; Hayes RJ; Dahiyat BI
    Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4005-10. PubMed ID: 16537476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism.
    Mishima Y; Terui Y; Mishima Y; Kuniyoshi R; Matsusaka S; Mikuniya M; Kojima K; Hatake K
    Int Immunol; 2012 Aug; 24(8):477-83. PubMed ID: 22438420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.
    Moore GL; Chen H; Karki S; Lazar GA
    MAbs; 2010; 2(2):181-9. PubMed ID: 20150767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering IgG1 Fc Domains That Activate the Complement System.
    Lee CH; Delidakis G
    Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered Fc-glycosylation switch to eliminate antibody effector function.
    Zhou Q; Jaworski J; Zhou Y; Valente D; Cotton J; Honey D; Boudanova E; Beninga J; Rao E; Wei R; Mauriac C; Pan C; Park A; Qiu H
    MAbs; 2020; 12(1):1814583. PubMed ID: 32892677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
    Raju TS
    Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
    Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
    PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IgG2m4, an engineered antibody isotype with reduced Fc function.
    An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
    MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
    Strome SE; Sausville EA; Mann D
    Oncologist; 2007 Sep; 12(9):1084-95. PubMed ID: 17914078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Contribution of IgG Glycosylation to Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC) in Hashimoto's Thyroiditis: An in Vitro Model of Thyroid Autoimmunity.
    Ząbczyńska M; Polak K; Kozłowska K; Sokołowski G; Pocheć E
    Biomolecules; 2020 Jan; 10(2):. PubMed ID: 31979029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
    Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular engineering to improve antibodies' anti-lymphoma activity.
    Peipp M; van de Winkel JG; Valerius T
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):217-29. PubMed ID: 21658620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells.
    Chung S; Lin YL; Reed C; Ng C; Cheng ZJ; Malavasi F; Yang J; Quarmby V; Song A
    J Immunol Methods; 2014 May; 407():63-75. PubMed ID: 24704820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical characterization of a new recombinant TNF receptor-hyFc fusion protein expressed in CHO cells.
    Lee JH; Yeo J; Park HS; Sung G; Lee SH; Yang SH; Sung YC; Kang JH; Park CS
    Protein Expr Purif; 2013 Jan; 87(1):17-26. PubMed ID: 23009882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
    Branstetter E; Duff RJ; Kuhns S; Padaki R
    FEBS Open Bio; 2021 Nov; 11(11):2943-2949. PubMed ID: 34355537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.
    Nechansky A; Schuster M; Jost W; Siegl P; Wiederkum S; Gorr G; Kircheis R
    Mol Immunol; 2007 Mar; 44(7):1815-7. PubMed ID: 17011625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
    van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
    Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.
    Lo M; Kim HS; Tong RK; Bainbridge TW; Vernes JM; Zhang Y; Lin YL; Chung S; Dennis MS; Zuchero YJ; Watts RJ; Couch JA; Meng YG; Atwal JK; Brezski RJ; Spiess C; Ernst JA
    J Biol Chem; 2017 Mar; 292(9):3900-3908. PubMed ID: 28077575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TNF receptor II fusion protein with tandemly repeated Fc domains.
    Nagashima H; Kaneko K; Yamanoi A; Motoi S; Konakahara S; Kohroki J; Masuho Y
    J Biochem; 2011 Mar; 149(3):337-46. PubMed ID: 21278157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
    Peipp M; Lammerts van Bueren JJ; Schneider-Merck T; Bleeker WW; Dechant M; Beyer T; Repp R; van Berkel PH; Vink T; van de Winkel JG; Parren PW; Valerius T
    Blood; 2008 Sep; 112(6):2390-9. PubMed ID: 18566325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.